Open Menu
Meetings & Education
Meetings & Education
Research & Data
Practice & Patients
Career Development
News & Initiatives
Get Involved
Phase II study evaluating olutasidenib and azacitidine in patients with IDH1-mutated higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or advanced myeloproliferative neoplasms.
Background:
IDH1 mutations are detected in 3-4% of patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) and approximately 9% of patients with myeloproliferative neoplasms (MPN). IDH1 mutations have been associated with shortened survival and increased rates of transformation to acute myeloid leukemia (AML). Despite the use of IDH1 inhibitors in AML and the recent FDA approval of ivosidenib for relapsed/refractory IDH1-mutated MDS, no IDH1-directed therapies are approved in MPN or treatment-naĂŻve MDS/CMML, and no combination treatment regimens are commercially available.
Olutasidenib, an FDA-approved oral, highly selective, potent inhibitor of mutant IDH1, is well-tolerated, non-cytotoxic and effective, with overall response rates in relapsed/refractory AML of 51% in combination with azacitidine. Olutasidenib alone or with azacitidine demonstrated overall response rates of 86% in treatment-naĂŻve and 47% in relapsed/refractory MDS. We consequently hypothesize olutasidenib to be effective in patients with IDH1-mutated higher-risk MDS/CMML or advanced MPN.
Methods:
This multicenter investigator-initiated study under the MDACC-Rigel Research Alliance is a phase II non-randomized study evaluating the efficacy of olutasidenib in combination with azacitidine in patients with IDH1-mutated higher-risk MDS/CMML or advanced MPN. Patients will be divided into 2 arms: treatment naïve and previously treated. Eligibility includes adult patients with acceptable organ function and confirmed IDH1 mutation with higher-risk MDS/CMML (by International Prognostic Scoring System [IPSS], Revised IPSS [IPSS-R], or Molecular IPSS [IPSS-M] criteria) or advanced MPN (with bone marrow blast percentage ≥ 10%).
The primary objective of the study is to determine the overall response rate by International Working Group 2023 criteria (MDS), 2015 MDS/MPN uniform response criteria (CML), and European Leukemia Network 2017 AML criteria (advanced MPN). Secondary objectives include rates of complete remission, safety and tolerability, overall survival, progression-free survival, duration of response, and changes in IDH1 clone size.
All patients will receive azacitidine 75 mg/m2 intravenously or subcutaneously daily on days 1-7 of each treatment cycle and olutasidenib 150 mg orally twice daily. Response assessments will be performed after cycle 1, then every 3 cycles up through cycle 12, then every 12 cycles thereafter. Once off treatment, survival follow-up will occur every 3 months for 3 years.
The goal enrollment is 45 patients (25 treatment-naĂŻve and 20 previously-treated with no more than 5 MPN patients in each arm) across 5-6 centers in the United States. The study was activated and enrollment began in January 2025 (ClinicalTrials.gov ID: NCT06597734).
Disclaimer
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Author Details
Kelly Chien
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Authors chevron_right
Associated Organizations chevron_right
Abstract Details
Meeting
2025 ASCO Annual Meeting
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
View MoreAbstract Disclosure
open_in_new
Your Privacy
ASCO is committed to transparency regarding our websites and the ways we process data. When you visit our site, we may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, your location, or your device and is mostly used to make the site work as you expect it to and to personalize your web experience with us.
Because we respect your right to privacy, you can choose not to allow some or all types of cookies. Click on the different category headings to find out more about the types of cookies used on our websites and change your default settings to match your preferences. Please read these carefully. Blocking some types of cookies may impact your experience on the site, including our ability to personalize the content you receive from us.
For a full explanation of the personal and non-personal information we collect on our site, including how we use that information and your rights regarding that information, please review our Privacy Policy. Use of our website is also subject to our Terms of Use.
Allow All
Manage Consent Preferences
Essential Website Cookies
Always Active
These cookies are necessary for the website to function and are sometimes referred to as “strictly necessary” cookies. They make sure the website delivers you information and services in an optimal way.
They are often set in response to an action you take, such as changing your cookie preferences, setting your privacy preferences, logging in to our website, asking the site to remember you on subsequent pages, or filling in forms. These cookies do not identify you personally.
You can set your browser to block or alert you about all cookies, including essential website cookies, but some parts of the site will not work as a result.
Cookies Details‎
Performance and Functionality Cookies
Performance and Functionality Cookies
These cookies enhance the performance and functionality of our websites and the services we provide. For example, these cookies can keep track of your visitor session in between visits, enable you to share content through social media, use embedded media players, and use comment features. They also help us balance website load and improve site speed and performance.
All information these cookies collect is aggregated and therefore anonymous. These cookies may be set by us or by third party providers whose services we have added to our websites. These cookies are non-essential, but without these cookies, certain functionality or enhanced features may become unavailable.
Cookies Details‎
Personalization and Analytics Cookies
Personalization and Analytics Cookies
These cookies collect information that is used to help us understand how our websites and content are used, help us customize our websites and application for you in order to enhance your experience, and help us improve the content that ASCO creates to better meet our members’ and visitors’ needs. Examples include cookies that show us which content might be most popular with our visitors, understand browsing history of our users, understand the effectiveness of our own advertising, and enable us to recommend content to individual users based on their profile and activities on the website.
These cookies may be set by us or by third party providers whose services we have added to our websites.
These cookies are non-essential to the functionality of the site and may contain information that enables us or our third party providers to identify you and build a profile of your interests. Without these cookies, you will not be able to have a customized or personalized experience within our website.
Cookies Details‎
Advertising Cookies and Social Media Cookies
Advertising Cookies and Social Media Cookies
Advertising (or Targeting) cookies are third party cookies that may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant ads on other sites.
Social Media Cookies are cookies set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your activities across other sites and building a profile of your interests. This may impact the content and messages you see on other websites you visit.
These cookies and the data collected by the third parties may be combined with data from other users or data about your activity on other sites. While the data collected on our site is aggregate or non-personal, the data may be used by such third parties to link you on other platforms or otherwise identify you.
If you do not allow these cookies, you may experience less targeted advertising.
Cookies Details‎
Back Button
Cookie List
Search Icon
Filter Icon
Clear
checkbox labellabel
ApplyCancel
ConsentLeg.Interest
checkbox labellabel
checkbox labellabel
checkbox labellabel
View Cookies
Name
cookie name
Save Settings
Download